Navigation Links
AGA Medical Corporation Receives Approval for the AMPLATZER Muscular Ventricular Septal Defect Occluder
Date:9/10/2007

MINNEAPOLIS, Sept. 10 /PRNewswire/ -- AGA Medical Corporation ("AGA") announced today that it has received U.S. Food and Drug Administration (FDA) approval to market the AMPLATZER Muscular Ventricular Septal (VSD) Occluder.

The AMPLATZER Muscular VSD Occluder is intended in patients for transcatheter closure of a complex ventricular septal defect of a sufficient size to warrant closure (large volume left to right shunt, pulmonary hypertension and/or clinical symptoms of congestive heart failure). The patient must also be considered at high risk for surgical closure based either on the anatomy of the defect or the patient's overall medical condition. VSDs typically occur in infants and are the most common type of congenital heart defect.

"We are pleased to make the Muscular VSD Occluder available for our U.S. physician customers," said Franck Gougeon, President and CEO of AGA. "The VSD, along with the previously approved AMPLATZER Septal Occluder and AMPLATZER Duct Occluder, provide U.S. cardiologists with the most comprehensive set of tools from any single company to treat structural heart disease."

The AMPLATZER Muscular VSD Occluder consists of two discs made of self expanding nitinol. The device is implanted via a catheter, a procedure that is a less-invasive alternative to open heart surgery and results in shorter recovery time. To increase the closing ability, the discs are filled with polyester fabric that is secured to the disc. The Muscular VSD Occluder uses the unique AMPLATZER interface between the device and delivery cable. This screw attachment permits the device to be retrieved and repositioned prior to release from the cable.

As part of the approval conditions, AGA has agreed to conduct a five-year post approval study to evaluate long-term safety and effectiveness. In addition, AGA will enroll at least 100 patients in a prospective registry study that will include an evaluation of immediate post-procedural technical success, occurrence of major complications acutely and over designated time intervals, as well as longer term success in closing the shunt associated with the VSD.

ABOUT AGA MEDICAL: AGA Medical Corporation, based in Plymouth, Minnesota (just outside Minneapolis), is the leader in developing interventional devices to treat structural heart defects. As a result of the many contributions and creative genius of Dr. Kurt Amplatz, the company has developed and commercialized a series of devices that have revolutionized the treatment of the most common congenital "holes in the heart," such as atrial septal and patent foramen ovale defects. The company is expanding into new areas, including the minimally invasive repair of vascular abnormalities. Over 700 articles have been published in peer reviewed medical publications that support the benefits of AGA Medical devices, such as improved patient outcomes, reduced length of stay and accelerated recovery times for the patient. AGA Medical devices have received regulatory approval and are marketed in over 90 countries with over 250,000 devices shipped to date. For more information visit http://www.amplatzer.com.

MEDIA CONTACT:

Jake Sargent

Brunswick Group LLC

202.393.7337

jsargent@brunswickgroup.com


'/>"/>
SOURCE AGA Medical Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Check if your “Favourite medical web-site” is indulging in Quackey
2. Teens turning to Internet for medical queries
3. Robots craft medical history
4. NBE to conduct test for medical students from abroad
5. Air pollution combined with greater medical needs
6. Indian Nationals with Foreign Medical Degrees can now practice in India
7. Children! Protecting them from medical mistakes
8. More information sought by patients on medical errors
9. SARS necessitates medical masks
10. Meditation Works Medically
11. Sleep Disorders Could Indicate Other Medical Problems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... New York City, NY (PRWEB) , ... March ... ... governing body for men’s and women’s professional squash, announced it has enlisted New ... marketing partner. The agency will develop and procure sponsorship opportunities for the ...
(Date:3/29/2017)... ... March 30, 2017 , ... Youth Futures International (YFI) premiered its Serve, Learn, ... school and college students who have participated in the program every summer. The ... now accepting applications for enrollment. Visit http://www.ghana.yfiexperience.org to learn more. , ...
(Date:3/29/2017)... Baton Rouge, Louisiana (PRWEB) , ... March 29, ... ... trademarked HeartBoost in three Hours at a Walgreens store in Mississippi. AngioGenesis Labs, ... campaign at Walgreens Stores in two southeastern states. Ingredients in HeartBoost, an over ...
(Date:3/29/2017)... ... 2017 , ... Dr. Angela Cotey, a noted general dentist in Mt. Horeb, ... with or without a referral. Dr. Cotey knows that interceptive orthodontics in ... When patients receive early treatment, they may achieve straight teeth with less treatment in ...
(Date:3/29/2017)... MD (PRWEB) , ... March 29, 2017 , ... ... is proud to announce the finalization of the company’s executive management team with prominent ... and leading operations is Curio Wellness’ Chief Operating Officer, Ted Dumbauld , who ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... N.J. , March 29, 2017  Novartis ... Administration (FDA) has accepted the company,s Biologics License ... CTL019 (tisagenlecleucel-T), an investigational chimeric antigen receptor T ... pediatric and young adult patients with B-cell acute ... submission by Novartis for a CAR-T. The priority ...
(Date:3/29/2017)... -- The Global Health Innovative Technology Fund (GHIT Fund), ... infectious diseases around the globe, today announced 11 ... deliver a range of new innovative therapies for ... This latest round of targeted support includes funding ... pediatric formulation of a drug considered the gold ...
(Date:3/29/2017)... March 29, 2017 Optometrists have staunchly ... the highest standard in quality and care for ... its objective Wavefront-driven refraction technologies and process to ... enables an unprecedented level of refraction and correction ... relegated to Topgun Navy fighter pilots, but now ...
Breaking Medicine Technology: